Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1995-06-27
1999-09-21
Richter, Johann
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514247, 514252, 514253, 514256, 514262, 514263, 514264, 514307, 514311, 514357, 514365, 514372, 514374, 514378, 514381, 514383, 514397, 514399, 514400, 514405, 514406, 514411, 514428, 514432, 514438, 514443, 514456, 514464, 514465, 544224, 544242, 544264, 544353, 546138, 546139, 546336, 548125, 548127, 548128, 548131, 548143, 548202, 548214, 548235, 548237, 548240, 548250, 548255, 5482622, 5483351, 5483611, 5483731, 548440, 548469, 548561, 549 23, 549 29, 549 32, 549362, A61K 31405, A61K 31195, A61K 3141, A
Patent
active
059554916
ABSTRACT:
The present invention provides a cathepsin L inhibitor containing a compound of the formula: ##STR1## wherein R.sup.1 is a hydrogen atom or an arylalkyl, heterocyclic-alkyl or lower alkyl group which may be substituted; R.sup.2 and R.sup.3 independently are a hydrogen atom or a hydrocarbon residue which may be substituted; R.sup.4 is an alkanoyl, sulfonyl, carbonyloxy, carbamoyl or thiocarbamoyl group which may be substituted; X is formula: --CHO or --CH.sub.2 OB (wherein B is a hydrogen atom or a protecting group of hydroxyl group); m and n independently are an integer of 0 or 1; provided that R.sup.4 is an alkanoyl group substituted by aryl, a sulfonyl group substituted by aryl having more than 9 carbon atoms or by lower alkyl, or a carbamoyl or thiocarbamoyl group which may be substituted when R.sup.1 is an unsubstituted lower alkyl, arylalkyl on methylthioethyl group, R.sup.2 and R.sup.3 independently are a lower alkyl or arylalkyl, X is --CHO, m is 1 and n is 0 or 1, or a salt thereof.
REFERENCES:
patent: 5498728 (1996-03-01), Sohda et al.
Pilbeam et al., "Inhibition by 17B Estradiol of PTH Stimulated Resorption and Prostaglandin Production in cultured Neonatial Mouse Calvariae", Biochem. and Biophys. Res. Comm., vol. 163, No. 3, pp. 1319-1324, Sep. 29, 1989.
Eriksen et al., "Evidence of Estrogen Receptors in Normal Human Osteoblast-like Cells," Science, vol. 241, pp. 84-86, Jul. 1, 1988.
Morris Notelovitz, "Estrogen Therapy and Osteoporosis: Principles & Practice," The American J. of the Medical Sciences, vol. 313, No. 1, pp. 2-12, Jan. 1, 1997.
Driguez et al., Canadian Journal of Chemistry, vol. 56, pp. 119-130 (1978).
Towatari et al., FEBS Letters, vol. 280, No. 2, pp. 311-315 (1991).
Aoyagi et al., The Journal of Antibiotics, vol. 22, No. 6, pp. 283-286 (1969).
Hanada et al., Agricultural and Biological Chemistry, vol. 42, No. 3, pp. 523-528 (1978).
Hanada et al., Agricultural and Biological Chemistry, vol. 42, No. 3, pp. 537-541 (1978).
Hanada et al., Agricultural and Biological Chemistry, vol. 42, No. 3, pp. 529-536 (1978).
Murata et al., FEBS Letters, vol. 280, No. 2, pp. 307-310 (1991).
Fujisawa Yukio
Kori Masakuni
Mizoguchi Junji
Sohda Takashi
Takizawa Masayuki
Conlin David G.
Oswecki Jane C.
Resnick David S.
Richter Johann
Takeda Chemical Industries Ltd.
LandOfFree
Method for treating osteoporosis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating osteoporosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating osteoporosis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-80703